deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03569280

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sponsor: Kangpu Biopharmaceuticals, Ltd.

Conditions Castration-Resistant Prostate Cancer
Interventions Enzalutamide or Abiraterone or Apalutamid
Updated 16 times since 2018 Last updated: Jul 16, 2023 Started: Nov 26, 2019 Primary completion: Jan 10, 2023 Completion: Jun 15, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Castration-Resistant Prostate Cancer and is currently completed. Kangpu Biopharmaceuticals, Ltd. leads this study, which shows 16 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Jun 2019 · 7 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2022 · 14 months · monthly snapshot~May 2022 – ~Mar 2023 · 10 months · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Jul 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1

  5. Jun 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE1

▶ Show 11 earlier versions

  1. Mar 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. May 2022 — Mar 2023 [monthly]

    Recruiting PHASE1

  3. Mar 2021 — May 2022 [monthly]

    Recruiting PHASE1

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  5. Jan 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  6. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  7. Sep 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  8. Jun 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

  9. Nov 2018 — Jun 2019 [monthly]

    Recruiting PHASE1

  10. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  11. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kangpu Biopharmaceuticals, Ltd.
Data source: Kangpu Biopharmaceuticals, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations